Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BC02
- Development stage
- Unknown
- Lead developer
- Anhui Zhifei Longcom Biopharmaceutical
- Modality
- Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular
01
Overview
BC02 is a proprietary compound vaccine-adjuvant system comprising BCG-derived CpG DNA, also termed BC01, and aluminum hydroxide. The CpG DNA component activates Toll-like receptor 9 to promote innate immune activation and antigen-specific cellular and humoral immune responses, while aluminum hydroxide serves as an inorganic salt adjuvant and delivery component. BC02 is used in the recombinant tuberculosis vaccine AEC/BC02, which has entered Phase 2 clinical testing for latent tuberculosis infection, and has also been evaluated preclinically with varicella-zoster virus glycoprotein E and human papillomavirus virus-like-particle antigens. ([mdpi.com](https://www.mdpi.com/2076-393x/10/12/2155))
- Other names
- BCG CpG DNA compound adjuvant system 02BCG-CpG-DNA compound adjuvant system 02
02
Targets
TLR9 (Toll-like receptor 9)
Beyond the preview
Go deeper on BC02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BC02.